Products
Products
Our pipeline
Delivering first-in-class immunotherapies
of activation and regulation
OSE Immunotherapeutics’ team has unique expertise and experience in immunological target discovery that serves as the basis for the development of innovative agonists and antagonists for application in immuno-oncology and autoimmune diseases.
We have already developed several first-in-class products that activate or regulate the immune system and cover a wide range of clinical indications, generating several academic and pharma partnerships.
OSE Immunotherapeutics’ pipeline is currently comprised of six developmental projects, four in immuno-oncology and two in autoimmune diseases. Five of our candidates are currently in the clinic.
Program
Indication
Humanized
lead
lead
Pre-Clinical
POC
POC
Phase 1
Phase 2
Phase 3
Partners
Immuno-oncology
Tedopi®
Neo-Epitopes
Neo-Epitopes
NSCLC
EU-US-lsrael
Tedopi®
Neo-Epitopes
Neo-Epitopes
Advanced pancreatic cancer
Combo with PD1 Opdivo® ongoing

BI 765063 (OSE-172)
SIRPα
SIRPα
Advanced solid tumours
Ongoing

OSE-703
IL-7 R
IL-7 R
Various cancers
2019

Program
- Indication NSCLC
- Humanized
- Pre-Clinical POC
- Phase 1
- Phase 2
- Phase 3 EU-US-lsrael
- Partners
Program
Indication
Humanized
lead
lead
Pre-Clinical
POC
POC
Phase 1
Phase 2
Phase 3
Partners
Auto-immune diseases
FR104
CD-28
CD-28
Auto-immune diseases & Transplantation
2019
OSE-127
IL-7 R
IL-7 R
UC Sjögren
Positive Phase 1 results Q4 2019
2020
